Table 1.
Clinical characteristics of 352 patients with CML, BPa
| Groups | All BP (N= 352) | MyBP (N= 241) | LyBP (N= 111) | ||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|||||||
| Parameter | With ACAs | Without ACAs | P value | With ACAs | Without ACAs | P value | With ACAs | Without ACAs | P value |
| No. (%) | 271 (77) | 81 (23) | 192 (79.7) | 49 (20.3) | 79 (71.2) | 32 (28.8) | |||
| Sex | |||||||||
| Male (N, %) | 171 (63.1) | 40 (49.4) | 118 (61.5) | 19 (38.8) | 53 (67.1) | 21 (65.6) | |||
| Female (N, %) | 100 (36.9) | 41 (50.6) | 0.03 | 74 (38.5) | 30 (61.2) | 0.004 | 26 (32.9) | 11 (34.4) | 0.88 |
| Age (years) | |||||||||
| Median | 52.1 | 48.6 | 52.4 | 55.1 | 50.8 | 46.6 | |||
| Range | 13.2–92.4 | 17.6–90.2 | 15.4–92.4 | 23.3–90.2 | 13.2–77.0 | 17.6–72.9 | |||
| Interval (months) | |||||||||
| Median | 23 | 23.3 | 25.3 | 25 | 11.9 | 11.9 | |||
| Range | 0–232.1 | 0–225.5 | 0–232.1 | 0–193.8 | 0–210.7 | 0–225.5 | |||
| Status at last F/U | |||||||||
| Alive (N, %) | 69 (25.5) | 25 (30.9) | 39 (20.3) | 13 (26.5) | 30 (38.0) | 12 (37.5) | |||
| Dead (N, %) | 202 (74.5) | 56 (69.1) | 0.33 | 153 (79.7) | 36 (73.5) | 0.35 | 49 (62) | 20 (62.5) | 0.96 |
| Tx response | |||||||||
| HR (N, %) | 136/257 (52.9) | 59/79 (74.7) | 0.0006 | 83/180 (46.1) | 32/47 (68.1 ) | 0.007 | 53/77 (68.8) | 27/32 (84.4) | 0.09 |
| CCyR (N, %) | 79/257 (30.7) | 31/79 (39.2) | 0.16 | 40/180 (22.2) | 15/47 (31.9) | 0.17 | 39/77 (50.6) | 16/32 (50) | 0.95 |
| MMR (N, %) | 60/257 (23.4) | 23/78 (29.5) | 0.27 | 29/180 (16.1) | 11/47 (23.4) | 0.24 | 31/77 (40.2) | 12/31 (38.7) | 0.88 |
| Allo-HSCT (N, %) | 70/260 (26.9) | 17/79 (21.5) | 0.34 | 40/182 (22) | 9/48 (18.8) | 0.63 | 30/78 (38.5) | 8/31 (25.8) | 0.21 |
Abbreviations: Age, age at diagnosis of BP; F/U, follow-up; Interval, interval time from the CML diagnosis to the BP diagnosis; Tx, treatment.
Of total 352 patients, 329 were diagnosed with CML initially in CP/AP, and 323 of them (323/329, 98.2%) received TKIs. Of all 352 patients in this cohort, 311 (311/352, 88.4%) received TKIs during BP. Not all patients had treatment response information or status of transplantation available at the last follow-up. Clinical features between different groups were compared using the χ22 test and the Spearman rank correlation. ACA was defined as any additional chromosomal abnormalities in Philadelphia chromosome-positive (Ph+) cells. Chromosomal changes in Philadelphia chromosome-negative cells were not considered as ACAs. BP was defined as 20% or more blasts in peripheral blood or bone marrow. Hematologic response was defined as <5% blasts in bone marrow and 0% in peripheral blood. Complete cytogenetic response was defined as 0% Ph+ metaphases using conventional karyotyping analysis of at least 20 metaphases. Major molecular response was defined as BCR-ABL1:ABL1 transcript ratio ⩽0.1%.